Alembic Pharma shares hit upper circuit after Q2 PAT surge
In short
Alembic Pharma shares hit the 20% upper circuit after its quarterly profit rose 81% year on year. Revenue from operations also rose 36% to ₹2,603 crore from ₹1,910 crore a year ago.
The stock move shows investors liked the result, but the reporting does not say what caused the stronger profit. What is still unknown is the detailed reason behind the performance.
What the reporting says
Alembic Pharma shares hit the 20% upper circuit after the company reported an 81% year-on-year rise in quarterly profit, according to the published market summary. Revenue from operations also increased 36% to ₹2,603 crore from ₹1,910 crore a year earlier. The reporting does not say what drove the jump, and only the share reaction and financial figures are stated.
Why it matters
Alembic Pharma reported an 81% year-on-year rise in quarterly profit, while revenue from operations increased 36% to ₹2,603 crore from ₹1,910 crore a year earlier. The market response was immediate, with the stock hitting the 20% upper circuit. The available reporting does not state the margin trend, guidance, or the specific business drivers behind the results.